-
1.发明授权公开(公告)号：US07452524B2
公开(公告)日：2008-11-18
申请号：US11045234
申请日：2005-01-28
CPC分类号： A61K9/0075 , A61K9/0078 , A61K9/008
摘要： A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.
摘要翻译： 一种用于改善通过吸入递送的治疗有效药物的耐受性的方法，其包括在给予主要治疗有效药剂之前立即施用或至多约30分钟施用雾化的利多卡因或利多卡因样化合物的患者的预处理。 患有雾化利多卡因或利多卡因样化合物的患者的预处理改善了气道耐受性并且将药物沉积在肺中，并使得沉积更安全，有效，可控和可预测。 本发明的方法对于增强免疫抑制剂在移植患者的肺中的沉积特别有用，通过减少咳嗽改善药物的耐受性并改善肺部药物沉积。
-
2.发明授权Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks 失效目标输送利多卡因和其他局部麻醉剂，以及治疗咳嗽和咳嗽发作的方法公开(公告)号：US07452523B2
公开(公告)日：2008-11-18
申请号：US11045226
申请日：2005-01-28
CPC分类号： A61K9/0075 , A61K9/0078 , A61K9/008
摘要： An anti-tussive nebulized solution for targeted delivery of lidocaine into conducting and central airways. A method for treatment of cough and tussive attacks or episodes using said lidocaine solution. A nebulized lidocaine solution administered in daily dose from about 10 mg to 80 mg of lidocaine dissolved in a saline and nebulized into an aerosol having a mass median aerodynamic diameter 3 μm to 10 μm and a geometric standard deviation less than 1.7 using an electronic nebulizer.
摘要翻译： 一种用于将利多卡因有针对性地输送到导管和中央气道中的抗咳嗽雾化溶液。 使用利多卡因溶液治疗咳嗽和咳嗽发作或发作的方法。 雾化的利多卡因溶液以约10mg至80mg的溶解在盐水中的利多卡因和使用电子雾化器雾化成质量中值空气动力学直径3mum至10um，几何标准偏差的气溶胶施用。
-
3.发明申请公开(公告)号：US20090004279A1
公开(公告)日：2009-01-01
申请号：US12208247
申请日：2008-09-10
IPC分类号： A61K9/14 , A61K31/167 , A61K31/545 , A61K38/12 , A61K31/7036 , A61K31/403 , A61K31/431 , A61K38/00 , A61K31/397 , A61K31/665 , A61K31/395 , A61K31/547 , A61K31/444 , A61K38/06 , A61K31/155 , A61K31/44 , A61K31/277 , A61K31/341 , A61P43/00 , A61K31/727 , A61K31/573 , A61K31/50 , A61K31/4162 , A61K31/343 , A61K31/335
CPC分类号： A61K9/0075 , A61K9/0078 , A61K9/008
摘要： A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.
摘要翻译： 一种用于改善通过吸入递送的治疗有效药物的耐受性的方法，其包括在给予主要治疗有效药剂之前立即施用或至多约30分钟施用雾化的利多卡因或利多卡因样化合物的患者的预处理。 患有雾化利多卡因或利多卡因样化合物的患者的预处理改善了气道耐受性并且将药物沉积在肺中，并使得沉积更安全，有效，可控和可预测。 本发明的方法对于增强免疫抑制剂在移植患者的肺中的沉积特别有用，通过减少咳嗽改善药物的耐受性并改善肺部药物沉积。
-
4.发明授权公开(公告)号：US08003081B2
公开(公告)日：2011-08-23
申请号：US12208247
申请日：2008-09-10
CPC分类号： A61K9/0075 , A61K9/0078 , A61K9/008
摘要： A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.
摘要翻译： 一种用于改善通过吸入递送的治疗有效药物的耐受性的方法，其包括在给予主要治疗有效药剂之前立即施用或至多约30分钟施用雾化的利多卡因或利多卡因样化合物的患者的预处理。 患有雾化利多卡因或利多卡因样化合物的患者的预处理改善了气道耐受性并且将药物沉积在肺中，并使得沉积更安全，有效，可控和可预测。 本发明的方法对于增强免疫抑制剂在移植患者的肺中的沉积特别有用，通过减少咳嗽改善药物的耐受性并改善肺部药物沉积。
-
5.发明授权Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough, asthma and tussive attacks 失效针对性地输送利多卡因和其他局部麻醉药以及治疗咳嗽，哮喘和咳嗽发作的方法公开(公告)号：US07998463B2
公开(公告)日：2011-08-16
申请号：US12208219
申请日：2008-09-10
CPC分类号： A61K9/0075 , A61K9/0078 , A61K9/008
摘要： An anti-tussive nebulized solution for targeted delivery of lidocaine into conducting and central airways. A method for treatment of cough and tussive attacks or episodes using said lidocaine solution. A nebulized lidocaine solution administered in daily dose from about 10 mg to 80 mg of lidocaine dissolved in a saline and nebulized into an aerosol having a mass median aerodynamic diameter 3 μm to 10 μm and a geometric standard deviation less than 1.7 using an electronic nebulizer.
摘要翻译： 一种用于将利多卡因有针对性地输送到导管和中央气道中的抗咳嗽雾化溶液。 使用利多卡因溶液治疗咳嗽和咳嗽发作或发作的方法。 雾化的利多卡因溶液以约10mg至80mg的溶解于盐水中的利多卡因和使用电子雾化器雾化成具有质量中值空气动力学直径3μm至10μm和几何标准偏差小于1.7的气雾剂的日剂量施用。
-
公开(公告)号：US20130014759A1
公开(公告)日：2013-01-17
申请号：US13548115
申请日：2012-07-12
IPC分类号： A61M16/16 , A61P31/04 , A61K31/7036
CPC分类号： A61K31/7036 , A61K9/0078 , A61K31/665 , A61K2300/00
摘要： The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.
-
7.发明申请Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections 有权用于治疗和预防肺细菌感染的可吸入的氨曲南溶解物制剂公开(公告)号：US20090028801A1
公开(公告)日：2009-01-29
申请号：US12229425
申请日：2008-08-21
CPC分类号： A61K31/427 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/008 , A61K31/198 , A61K31/397 , Y02A50/473 , Y10S514/837 , Y10S514/924 , Y10S514/932 , Y10S514/933 , Y10S514/951
摘要： A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
摘要翻译： 用于治疗由适用于治疗由大肠杆菌，肺炎克雷伯杆菌，克雷伯杆菌，铜绿假单胞菌，流感嗜血杆菌，奇异变形杆菌，肠杆菌属，粘质沙雷氏菌等引起的感染的革兰氏阴性细菌引起的肺细菌感染的方法和组合物，以及 由洋葱伯克霍尔德氏菌，嗜麦芽寡养单胞菌，产酪藓木糖苷和多药耐药铜绿假单胞菌引起的那些，使用作为气溶胶或干粉制剂递送的氨曲南溶解产物的浓缩制剂。
-
8.发明授权Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections 有权可吸入的氨曲南气雾剂用于治疗和预防肺细菌感染公开(公告)号：US07208141B2
公开(公告)日：2007-04-24
申请号：US10654815
申请日：2003-09-04
CPC分类号： A61K31/427 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/008 , A61K31/198 , A61K31/397 , A61K31/7036 , Y02A50/473
摘要： A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.
摘要翻译： 用于治疗由适用于治疗由大肠杆菌，肺炎克雷伯杆菌，克雷伯杆菌，铜绿假单胞菌，流感嗜血杆菌，奇异变形杆菌，肠杆菌属，粘质沙雷氏菌等引起的感染的革兰氏阴性细菌引起的肺细菌感染的方法和组合物，以及 使用浓缩的氨曲南制剂或其药学上可接受的盐作为气溶胶或干粉制剂递送的那些由洋葱伯克霍尔德杆菌，嗜麦芽寡养单胞菌，产酪藓木糖苷和多药耐药铜绿假单胞菌引起的。
-
9.发明申请FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS 审中-公开氨基甲酰胺和纤维蛋白结合物的配方以及用于治疗通气管相关PNEUMONIA（VAP）和通气管相关TRACHEAL（VAT）BRONCHITIS的方法和系统公开(公告)号：US20140221302A1
公开(公告)日：2014-08-07
申请号：US14232546
申请日：2012-07-12
IPC分类号： A61K31/7036 , A61K31/665
摘要： The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.
摘要翻译： 本发明是与呼吸机相关性肺炎（VAP）和呼吸机相关气管（VAT）支气管炎相关的抗生素组合物，基于呼吸机的系统和方法。 磷霉素和氨基糖苷类，优选阿米卡星的抗生素组合通过呼吸机气道内的直列雾化器施用。 加湿条件产生改善的气雾剂以处理VAP和增值税。
-
10.发明授权Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections 失效纯生物活性粘菌素，其组分和用于治疗肺部感染的粘菌素制剂
公开(公告)号：US5767068A
公开(公告)日：1998-06-16
申请号：US799300
申请日：1997-02-13
CPC分类号： A61K38/12
摘要： An anti-Pseudomonas aeruginosa agent which is substantially pure biologically active colistin, its component, a mixture thereof or a pharmaceutically acceptable salt thereof delivered as an aerosol or dry powder formulation. A formulation and method for preparation of substantially pure biologically active colistin, its components, mixtures thereof and a pharmaceutically acceptable salts thereof. A method for treatment and prophylaxis of Pseudomonas aeruginosa, Stenotrophomonas maltophilia or other susceptible pulmonary bacterial infections.
摘要翻译： 一种抗绿脓假单胞菌药物，其是基本上纯的生物活性粘菌素，其组分，其混合物或其药学上可接受的盐，其作为气雾剂或干粉制剂递送。 用于制备基本上纯的生物活性粘菌素，其组分，其混合物及其药学上可接受的盐的制剂和方法。 一种治疗和预防铜绿假单胞菌，嗜麦芽寡养单胞菌或其他易感性肺细菌感染的方法。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.026 秒)